ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Acerus Announces Publication of Study Results Demonstrating Effectiveness of NATESTO® Regardless of Baseline Symptom Severity
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 159366" data-attributes="member: 13851"><p><a href="https://www.accesswire.com/560652/Aytu-BioScience-Announces-Addition-of-NatestoR-to-Leading-National-Pharmacy-Benefit-Managers-Formulary-Natesto-Added-to-Commercial-Plans-Covering-Over-30-Million-US-Lives" target="_blank">Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives</a> </p><p></p><p></p><p><span style="font-size: 26px"><strong>Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives</strong></span></p><p></p><p></p><p><em><strong>During the 12-month period ending June 2019, the U.S. prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenue</strong></em></p><p></p><p><strong>ENGLEWOOD, CO / ACCESSWIRE / September 24, 2019 /</strong> <strong><span style="color: rgb(184, 49, 47)">Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, </span><span style="color: rgb(26, 188, 156)">today announced that Natesto® (testosterone nasal gel) is now on formulary and covered nationwide by a large, leading national pharmacy benefit manager</span> <span style="color: rgb(26, 188, 156)">(PBM).</span> <span style="color: rgb(44, 130, 201)">This PBM contract provides for unrestricted patient access to Natesto, the only FDA-approved nasally-administered testosterone therapy (TRT), across the PBM's commercial formularies.</span></strong></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Over thirty million U.S. lives are covered by these prescription plans nationwide.</strong></span> <span style="color: rgb(184, 49, 47)"><strong>These 30 million lives are in addition </strong></span><span style="color: rgb(26, 188, 156)"><strong>to the previously announced 6 million lives covered under a separate payer contract.</strong></span></p><p></p><p>During the 12-month period ending June 2019, the US prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenue.</p><p></p><p><strong>Josh Disbrow, Chief Executive Officer of Aytu BioScience stated, <span style="color: rgb(184, 49, 47)">"The addition of Natesto to this leading national PBM's formulary is a meaningful step in further building Natesto into a leading brand in the United States.</span></strong><span style="color: rgb(44, 130, 201)"><strong> With the signing of this second payer contract this year, over 36 million patients have gained access to Natesto in just the past three months. We believe this expanded coverage will increase physician prescribing of Natesto and enable improved access to the more than 13 million U.S. men diagnosed with hypogonadism."</strong></span></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Natesto is the only FDA-approved topically-applied therapy for low testosterone that does not have a black box warning related to transference of testosterone to children or women.</span></strong></p></blockquote><p></p>
[QUOTE="madman, post: 159366, member: 13851"] [URL="https://www.accesswire.com/560652/Aytu-BioScience-Announces-Addition-of-NatestoR-to-Leading-National-Pharmacy-Benefit-Managers-Formulary-Natesto-Added-to-Commercial-Plans-Covering-Over-30-Million-US-Lives"]Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives[/URL] [SIZE=26px][B]Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives[/B][/SIZE] [I][B]During the 12-month period ending June 2019, the U.S. prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenue[/B][/I] [B]ENGLEWOOD, CO / ACCESSWIRE / September 24, 2019 /[/B] [B][COLOR=rgb(184, 49, 47)]Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, [/COLOR][COLOR=rgb(26, 188, 156)]today announced that Natesto® (testosterone nasal gel) is now on formulary and covered nationwide by a large, leading national pharmacy benefit manager[/COLOR][COLOR=rgb(184, 49, 47)] [/COLOR][COLOR=rgb(26, 188, 156)](PBM).[/COLOR][COLOR=rgb(184, 49, 47)] [/COLOR][COLOR=rgb(44, 130, 201)]This PBM contract provides for unrestricted patient access to Natesto, the only FDA-approved nasally-administered testosterone therapy (TRT), across the PBM's commercial formularies.[/COLOR][/B] [COLOR=rgb(184, 49, 47)][B]Over thirty million U.S. lives are covered by these prescription plans nationwide.[/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]These 30 million lives are in addition [/B][/COLOR][COLOR=rgb(26, 188, 156)][B]to the previously announced 6 million lives covered under a separate payer contract.[/B][/COLOR] During the 12-month period ending June 2019, the US prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenue. [B]Josh Disbrow, Chief Executive Officer of Aytu BioScience stated, [COLOR=rgb(184, 49, 47)]"The addition of Natesto to this leading national PBM's formulary is a meaningful step in further building Natesto into a leading brand in the United States.[/COLOR][/B][COLOR=rgb(44, 130, 201)][B] With the signing of this second payer contract this year, over 36 million patients have gained access to Natesto in just the past three months. We believe this expanded coverage will increase physician prescribing of Natesto and enable improved access to the more than 13 million U.S. men diagnosed with hypogonadism."[/B][/COLOR] [B][COLOR=rgb(184, 49, 47)]Natesto is the only FDA-approved topically-applied therapy for low testosterone that does not have a black box warning related to transference of testosterone to children or women.[/COLOR][/B] [COLOR=rgb(243, 121, 52)][B][/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Acerus Announces Publication of Study Results Demonstrating Effectiveness of NATESTO® Regardless of Baseline Symptom Severity
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top